You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Exacerbations in non-COPD patients: truth or myth—authors’ response
  1. Wan C Tan1,
  2. Jean Bourbeau2,
  3. Shawn Aaron3,
  4. J Mark FitzGerald4,
  5. Paul Hernandez5,
  6. Robert Cowie6,
  7. Kenneth R Chapman7,
  8. Darcy Marciniuk8,
  9. Francois Maltais9,
  10. Sonia Buist10,
  11. Denis O'Donnell11,
  12. Don D Sin1
  13. for the CanCOLD Collaborative Research Group
  1. 1 UBC James Hogg Research Center, University of British Columbia Vancouver, British Columbia, Canada
  2. 2 McGill University, Respiratory, Montreal Chest Institute, Montréal, Quebec, Canada
  3. 3 Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
  4. 4 Department of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
  5. 5 Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
  6. 6 Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
  7. 7 Department of Respiratory Medicine, University of Toronto, Toronto, Ontario, Canada
  8. 8 Division of Respirology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
  9. 9 Centre de Pneumologie de l'hôpital Laval, Quebec City, Québec, Canada
  10. 10 Oregon Health and Science University, Portland, Oregon, USA
  11. 11 Division of Respiratory & Critical Care Medicine, Queen's University, Kingston, Ontario, Canada
  1. Correspondence to Dr Wan C Tan, UBC James Hogg Research Centre, Providence Heart + Lung Institute, University of British Columbia, St Paul's Hospital, Rm 166, 1081 Burrard Street, Vancouver, British Columbia, Canada V6Z 1Y6; wan.tan{at}hli.ubc.ca

https://doi.org/10.1136/thoraxjnl-2014-205889

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dear Sir,

    We are grateful to Dr Khurana and Dr Aggarwal for their interest1 in our paper.2

    On their first point, we agree that we should be careful about terminology. We evaluated a random sample of individuals representative of the general population rather than patients, so the findings that episodes of respiratory events occurred in these subjects would likely reflect real events in the general population. Furthermore, our study definition for exacerbations was the same standard questionnaire criteria for exacerbations used in clinical trials of selected patients with COPD.3

    On the second point on aetiologies for non-COPD subgroup in this study, we would like to emphasise that ‘non-COPD’ was defined by the absence of chronic airflow limitation using the standard, although arbitrary spirometric criteria. We excluded those individuals with self-reported chronic obstructive lung diseases, …

    View Full Text

    Footnotes

    • Contributors WCT drafted the response and finalised it. The other authors commented on the first draft and agreed with the final document.

    • Funding The Canadian Cohort of Obstructive Lung Disease (COLD/CanCOLD) is funded by the Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants- 93326); industry partners Astra Zeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., Nycomed Canada Inc., Pfizer Canada Ltd; and the Respiratory Health Network of the FRSQ. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

    • Competing interests WCT and JB report unrestricted educational grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca for the epidemiological COLD study; grants for the operations of the CanCOLD longitudinal epidemiological study from the Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants 93326) with industry partners AstraZeneca Canada, Boehringer Ingelheim Canada, GlaxoSmithKline Canada, Merck, Novartis Pharma Canada Inc., Nycomed Canada Inc., Pfizer Canada, outside the submitted work. WCT also received personal fees from GlaxoSmithKline board membership. DO'D reports grants from CIHR Research & Development during the conduct of the study. DM, an employee of the University of Saskatchewan, received funding from the Canadian Institutes of Health Research (via McGill University) to undertake this research. KRC received compensation for consulting with CSLBehring, GlaxoSmithKline, Grifols, Novartis, Roche and Takeda; has undertaken research funded by AstraZeneca, Boehringer-Ingelheim, CSLBehring, Forest Labs, GlaxoSmithKline, Johnson & Johnson, Novartis, Roche and Takeda, and has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Merck Frosst, Novartis, Nycomed, Pfizer and Talecris. PH reports grants from Canadian Institute of Health Research during the conduct of the study; grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Takeda, Grifols, CSL Behring, Pfizer, Almirall outside the submitted work. FM reports grants from GlaxoSmithKline, Boehringer Ingelheim, other from GlaxoSmithKline, Boehringer Ingelheim, Novartis, Griffols, Almirall, personal fees from Novartis, outside the submitted work. DDS reports personal fees from board membership, grants from/grants pending, personal fees from payment for lectures including service on speakers bureaus, other from travel to Denver for ATS (2011) outside the submitted work.

    • Ethics approval Institutional review board at each site.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles

    • PostScript
      Exacerbations in non-COPD patients: truth or myth
      Deepak Aggarwal Alkesh Kumar Khurana
      Thorax 2014; 69 1050-1050 Published Online First: 26 Jun 2014. doi: 10.1136/thoraxjnl-2014-205763
    • Respiratory epidemiology
      Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study
      W C Tan J Bourbeau P Hernandez K R Chapman R Cowie J M FitzGerald D D Marciniuk F Maltais A S Buist D E O'Donnell D D Sin S D Aaron for the CanCOLD Collaborative Research Group Jonathon Samet Milo Puhan Qutayba Hamid James C Hogg Jean Bourbeau Wan C Tan Carole Jabet Maria Sedona Palmina Mancino Yvan Fortier Don Sin Yuexin Li Sheena Tam Joe Comeau Adrian Ng Harvey Coxson Tara Candido Jonathon Leipsic Cameron Hague Jeremy Road Andrea Benedetti Carlo Mara Mohsen Savafi Andrea Gershon Teresa To Wan C Tan Harvey Coxson Jean Bourbeau Zhi L Pei Denis Jensen Denis O’Donnell Wan C Tan Christine Lo Jeong Min Carly Moy Anna La Lau Ashleigh Sran Ebony Swanson Ying Yuan Daniel Chen Lu Zheng Tina Yang Junior Chuang Best Guo Licong Li Kendall Chan Rahmath Khanam Daria Maslennikova Sarah Cheng Catherine Peng Bryan Chiang Sarah Guo Kyrsten Payne Jean Bourbeau Palmina Mancino Maria Sedona Carmen Darauay Myriam Costa Kenneth Chapman Patricia McClean Heather Sporn Robert Cowie Ann Cowie Curtis Dumonceaux Jessica Moore Paul Hernandez Scott Fulton Maria Yorke Natalie Fiorotos Ashley Rowe Shawn Aaron Kathy Vandemheen Gay Pratt Jeevitha Srighanthan Denis O’Donnell Kathy Webb Naparat Amornputtisathaporn Kate Cheung Kate Whelan Jenny Cheng Francois Maltais Joanie Couture Luciana Garcia Pereira Marie-Josée Breton Cynthia Brouillard Darcy Marciniuk Ron Clemens Janet Baran
      Thorax 2014; 69 709-717 Published Online First: 04 Apr 2014. doi: 10.1136/thoraxjnl-2013-205048